AMAG Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
AMAG AMAG Pharmaceuticals Inc
HCI Hci Group Inc
PSF Cohen & Steers Select Preferred and Income Fund
PJT PJT Partners Inc
ALK Alaska Air Group Inc
RS Reliance Steel & Aluminum Co
HFWA Heritage Financial Corp
MET MetLife Inc
KALU Kaiser Aluminum Corp
STBA S&T Bancorp Inc

Health Care : Biotechnology | Small Cap Value
Company profile

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

Closing Price
Day's Change
0.01 (0.07%)
B/A Size
Day's High
Day's Low

10-day average volume:

Fastly's stock pulls back after BofA analyst swings to bearish from bullish

11:01 am ET July 10, 2020 (MarketWatch)

Shares of Fastly Inc. (FSLY) sank 5.8% in morning trading, putting them on track to snap a streak of 3-straight record closes, after BofA Securities analyst Tal Liani swung to bearish from bullish on provider of real-time content delivery network services, citing valuation concerns. The stock has rocketed nearly fivefold (up 382%) year to date, compared with a 2.3% decline in the S&P 500 , as investors view the company as a COVID-19 beneficiary. Liani downgraded Fastly to underperform from buy, but raised its stock price target to $90, which is 6.9% below current levels, from $50, saying that while fundamentals are intact, valuation has become difficult to justify after the this year's run up. He said Fastly's new initiatives may take time to materialize, and "risks around execution and competition remain and are not reflected in the current valuation."

-Tomi Kilgore; 415-439-6400;

(END) Dow Jones Newswires

July 10, 2020 11:01 ET (15:01 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.